List of Excipients in Branded Drug KLARON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	KLARON	sulfacetamide sodium	0187-5198	EDETIC ACID
Bausch Health US LLC	KLARON	sulfacetamide sodium	0187-5198	HYDROXYETHYL CELLULOSE
Bausch Health US LLC	KLARON	sulfacetamide sodium	0187-5198	LAURIC DIETHANOLAMIDE
Bausch Health US LLC	KLARON	sulfacetamide sodium	0187-5198	METHYLPARABEN
Bausch Health US LLC	KLARON	sulfacetamide sodium	0187-5198	PEG-8 LAURATE

KLARON Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

KLARON is a prescription topical lotion containing 10% sulfacetamide sodium for acne vulgaris. Its commercial opportunity is primarily generic and formulation-led rather than patent-led. The product’s established excipient system is simple: water, fatty alcohols, glycerin, isopropyl myristate, methylparaben, and sodium thiosulfate. A competing product can pursue an authorized generic, an ANDA, a differentiated topical dosage form, or a reformulated sulfacetamide product with improved tolerability, preservation, packaging, and patient adherence.

The main technical challenge is maintaining sulfacetamide sodium stability and uniformity in a cosmetically acceptable, non-separating lotion. The main commercial challenge is limited market size, low barriers to basic generic entry, and competition from benzoyl peroxide, topical retinoids, clindamycin combinations, azelaic acid, and newer acne products.

What is KLARON and what formulation does it contain?

KLARON Lotion is a topical prescription product containing sulfacetamide sodium 10% w/w. The labeled indication is the topical treatment of acne vulgaris. Sulfacetamide is a sulfonamide antibacterial agent that inhibits bacterial folic-acid synthesis. The product is applied to affected skin, where vehicle performance affects spreadability, drying time, residue, and patient acceptance.

The labeled inactive ingredients are:

Excipient	Functional role
Purified water	Continuous phase and solvent
Cetyl alcohol	Emollient, viscosity builder, co-emulsifier
Stearyl alcohol	Emollient, structural wax, viscosity builder
Glycerin	Humectant and solvent
Isopropyl myristate	Emollient and spreading agent
Methylparaben	Antimicrobial preservative
Sodium thiosulfate	Stabilizing or compatibility-supporting excipient

The product is a lotion rather than a solution. The fatty alcohols provide body and emulsion structure, while glycerin supports hydration. Isopropyl myristate improves slip and spread but may create a commercial formulation concern because some acne patients and dermatology prescribers prefer vehicles marketed as non-comedogenic or low-residue. The label should control all composition and manufacturing comparisons. (U.S. Food and Drug Administration [FDA], n.d.-a)

What excipient strategy is most suitable for a KLARON generic?

The highest-probability strategy is a Q1/Q2-matched lotion with controlled changes to noncritical excipients, followed by a differentiated formulation only if the sponsor can support a clear commercial advantage.

Q1/Q2-matched lotion strategy

A close formulation match reduces development risk. The target profile should include:

• 10% w/w sulfacetamide sodium
• Comparable pH
• Comparable viscosity and rheology
• Comparable droplet size and emulsion structure
• Comparable appearance, odor, spreadability, and drying time
• Equivalent preservative performance
• Comparable in-use stability
• Consistent dose delivery from the selected container

The excipient system should preserve the existing roles of cetyl alcohol, stearyl alcohol, glycerin, methylparaben, and sodium thiosulfate unless a documented technical reason supports substitution.

Preservative strategy

Methylparaben is a conventional preservative, but it creates several development and positioning issues:

1. Preservative efficacy must be demonstrated in the finished emulsion.
2. The formulation must control microbial risk during manufacture and patient use.
3. A paraben-free version may support a pharmacy or dermatology marketing position, but replacing methylparaben may change pH, partitioning, emulsion stability, and preservative efficacy.
4. Phenoxyethanol, potassium sorbate, benzoic acid, or combination systems may require pH adjustment and compatibility work.

A paraben-free formulation is a potential commercial differentiator, but it is not automatically superior. The replacement must maintain antimicrobial protection without increasing irritation or destabilizing sulfacetamide sodium.

Humectant and sensory strategy

Glycerin supports hydration but can create tackiness at higher concentrations. A sponsor could evaluate propylene glycol, pentylene glycol, or blended polyol systems. These substitutions may alter:

• Skin feel
• Drying time
• Solubility
• Water activity
• Preservative performance
• Irritation potential
• Packaging interaction

For an acne lotion, low tack and rapid rub-in are commercially relevant. A formulation that feels lighter than the reference product may improve adherence, but that claim would require substantiation through sensory testing and, where necessary, comparative clinical or human-use studies.

Emollient strategy

Isopropyl myristate provides slip and spreadability. Its use should be evaluated against:

• Comedogenicity perception
• Oily residue
• Oxidative stability
• Compatibility with the emulsion system
• Interaction with package materials

Potential alternatives include caprylic/capric triglyceride, C12-15 alkyl benzoate, diisopropyl adipate, or lighter ester systems. These can improve sensory properties, but changes may affect drug partitioning, release from the vehicle, and skin deposition.

What formulation patents could protect a KLARON replacement?

The original KLARON product is unlikely to support a strong modern patent moat based solely on its basic excipient combination. Commercial protection would more likely arise from a new formulation, delivery system, manufacturing process, or use claim.

Potential patentable subject matter includes:

Strategy	Potential claim focus	Commercial value
Low-irritation lotion	Specific excipient ratios, pH, viscosity, and skin tolerability	Moderate
Paraben-free formulation	Alternative preservative system with stability and efficacy data	Moderate
Lightweight emulsion	Specific oil phase and rheology profile	Moderate
Foaming cleanser	Surfactant system, drug concentration, and rinse-off performance	Moderate
Hydrogel or emulgel	Polymer network and sulfacetamide release profile	Moderate
Spray or pump delivery	Dose uniformity, nozzle performance, and reduced contamination	Low to moderate
Unit-dose packaging	Stability, hygiene, and controlled administration	Low to moderate
Manufacturing process	Controlled particle size, hydration, mixing, or deaeration	Moderate
Combination product	Sulfacetamide with sulfur, niacinamide, or another acne active	High if clinically differentiated

A formulation patent must claim more than the presence of sulfacetamide sodium in a conventional topical base. Patent strength would depend on unexpected stability, release, tolerability, efficacy, or manufacturing advantages supported by comparative data.

What is the FDA regulatory status of KLARON?

KLARON is an FDA-approved prescription drug, not an over-the-counter acne product. A generic equivalent would generally proceed through the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Regulatory element	KLARON position
Active ingredient	Sulfacetamide sodium
Strength	10%
Dosage form	Lotion
Route	Topical
Indication	Acne vulgaris
Regulatory pathway for generics	ANDA, subject to FDA requirements
Biosimilar pathway	Not applicable
Main equivalence issues	Active ingredient, strength, dosage form, route, performance, and labeling

Because KLARON is a small-molecule topical drug, it is not a biosimilar candidate. The relevant competitive pathway is generic substitution, not the Biologics Price Competition and Innovation Act pathway.

FDA approval of a generic topical product may require more than simple chemical sameness. The sponsor must address product quality, inactive ingredients, microbiological quality, container closure, in vitro release, and any FDA-requested comparative performance evidence. FDA’s product-specific guidance and current ANDA recommendations should control the development program. (FDA, n.d.-b; FDA, 21 C.F.R. Part 314)

What is the Orange Book status and patent exposure of KLARON?

The FDA Orange Book identifies approved drug products, therapeutic equivalence information, and listed patent or exclusivity information where applicable. KLARON’s commercial exposure is expected to be driven more by legacy approval status and generic substitution than by an active, high-value patent estate.

The key regulatory questions are:

• Whether the reference product remains listed as the relevant reference listed drug
• Whether an ANDA applicant can identify KLARON as the reference product
• Whether any current patents are listed for the relevant strength and dosage form
• Whether any pediatric or other statutory exclusivity remains
• Whether the reference product has a current therapeutic-equivalence designation

The Orange Book is the controlling source for current patent listings and exclusivity status. A sponsor should not infer patent protection from historic product branding, formulation age, or discontinued litigation references. (FDA, n.d.-c)

When does KLARON lose exclusivity?

KLARON’s primary commercial exclusivity period is long past. The product has been marketed for decades, and its competitive position is not based on unexpired new-drug exclusivity.

The practical entry timeline depends on:

1. Reference listed drug status
2. ANDA development and FDA review
3. Paragraph IV certification, if an applicable listed patent exists
4. Product-specific guidance
5. Manufacturing readiness
6. Commercial channel access and substitution economics

A sponsor should assume that a basic generic lotion faces limited legal delay unless a currently listed patent or regulatory exclusivity creates a barrier. The most valuable protection for a new entrant may come from manufacturing scale, supply reliability, formulation differentiation, and payer or pharmacy contracting rather than patent litigation.

What Paragraph IV challenges could affect KLARON?

A Paragraph IV certification is relevant only if the ANDA applicant challenges a listed patent as invalid, unenforceable, or not infringed. For an old topical product with limited apparent patent exposure, the probability of a commercially significant Paragraph IV dispute is lower than for a recently approved branded drug.

Potential litigation issues would include:

• Whether the proposed product falls within a listed formulation claim
• Whether the applicant’s excipients avoid the claimed composition
• Whether the product infringes a process patent
• Whether the patent is properly listed for the reference product
• Whether a 30-month stay applies
• Whether the branded sponsor has commercial rights to enforce the patent

No biosimilar litigation pathway applies. Any litigation would be an ANDA or conventional patent action involving a small-molecule topical product. FDA’s Orange Book and the applicable ANDA certifications should be reviewed before assigning a litigation-adjusted launch date.

What formulation and dosage-form opportunities compete with KLARON lotion?

The strongest opportunity is not necessarily another identical lotion. Several dosage-form concepts could target specific patient or prescriber complaints.

Sulfacetamide sodium foam

A foam could offer rapid application, lower perceived greasiness, and improved use on larger affected areas. Development risks include:

• Drug crystallization during storage
• Propellant or pump compatibility
• Dose uniformity
• Foam collapse and delivery consistency
• Flammability or shipping constraints for pressurized systems

Sulfacetamide sodium cleanser

A rinse-off product could improve cosmetic acceptance and reduce residue. Its principal technical challenge is achieving adequate skin contact and drug delivery before rinsing. A cleanser may be positioned for acne or seborrheic dermatitis only if the proposed labeling and clinical evidence support the indication.

Sulfacetamide sodium emulgel

An emulgel can combine the spreadability of a lotion with the lower-residue profile of a gel. Carbomer, acrylate polymers, cellulose derivatives, or natural gums could be evaluated, but the sponsor must control:

• pH-dependent viscosity
• Electrolyte sensitivity
• Polymer-drug compatibility
• Preservative distribution
• Release from the gel matrix

Sulfacetamide and sulfur combination

A sulfacetamide-sulfur product may have a broader dermatology positioning than KLARON lotion. Sulfur introduces odor, color, particle dispersion, and stability challenges. The combination also creates a more defensible formulation platform if the dosage form, particle control, and performance provide a clinically meaningful advantage.

How strong is the KLARON patent estate?

The apparent patent strength is low for the legacy lotion as a standalone product. The basic composition uses conventional topical excipients, and the drug substance is an established sulfonamide antibacterial.

Patent strength would improve only where a sponsor can demonstrate:

• A non-obvious excipient combination
• Unexpected long-term stability
• Improved drug release or skin deposition
• Reduced irritation or sensitization
• Superior preservative protection
• A novel container or delivery system
• A clinically supported combination therapy
• A manufacturing process that produces a distinct and reproducible product

Trade-secret protection may be more practical than patent protection for process parameters, order of addition, deaeration, mixing energy, filling controls, and raw-material specifications. These measures will not prevent generic substitution, but they can reduce manufacturing failures and improve gross margin.

Which companies are likely to challenge KLARON commercially?

Competition is likely to come from three groups:

Competitor group	Products or strategy	Threat level
Generic topical manufacturers	Sulfacetamide sodium lotion or equivalent topical products	High
Dermatology generic specialists	Sulfacetamide, sulfur, and combination products	High
Branded acne manufacturers	Benzoyl peroxide, retinoids, clindamycin combinations, azelaic acid	Moderate to high

The most direct competitors are generic sulfacetamide sodium products. Indirect competitors include topical clindamycin, tretinoin, adapalene, benzoyl peroxide, dapsone, azelaic acid, and sulfacetamide-sulfur products. These products compete for the same dermatology prescribing budget even when they do not contain the same active ingredient.

What generic launch scenarios exist for KLARON?

Scenario 1: Exact or near-exact generic lotion

This is the lowest-risk path. It offers the fastest route to substitution but exposes the entrant to price erosion and limited differentiation.

Scenario 2: Premium-sensory generic

A lighter, faster-drying, paraben-free, or lower-residue lotion could support pharmacy, specialty-distributor, or dermatology-office adoption. Premium pricing would require credible product-level evidence and reliable supply.

Scenario 3: Alternative dosage form

A foam, gel, cleanser, or pump package could avoid direct lotion comparison and create a separate commercial position. Development and regulatory costs would be higher.

Scenario 4: Combination product

A sulfacetamide-sulfur product could target prescribers seeking antibacterial and keratolytic or antiseborrheic activity. This path has greater formulation complexity and may require a separate regulatory strategy.

What licensing deals and commercial partnerships could support KLARON?

The most practical licensing targets are:

• Existing topical dermatology manufacturers with unused capacity
• Companies holding proprietary emulsion or foam platforms
• Contract development and manufacturing organizations with semisolid experience
• Specialty generic companies with pharmacy distribution
• Dermatology companies seeking a low-cost portfolio product

A license should address formulation ownership, ANDA ownership, manufacturing rights, territory, technology-transfer obligations, minimum purchase commitments, pharmacovigilance, recalls, and responsibility for postapproval changes.

There is limited strategic value in licensing a basic KLARON copy unless the partner contributes one of four assets: an approved ANDA, a differentiated dosage form, a validated manufacturing platform, or established dermatology distribution.

What geographic markets offer the best opportunity?

The United States offers the clearest substitution opportunity because of the ANDA and Orange Book framework. Canada, Europe, Australia, and selected emerging markets may offer opportunities, but approval and substitution rules differ.

Key geographic considerations include:

• U.S. therapeutic-equivalence and pharmacy substitution rules
• European national or decentralized authorization requirements
• Country-specific status of sulfonamide topical products
• Local excipient acceptability
• Preservative restrictions
• Packaging and labeling requirements
• Dermatology prescribing patterns
• Reimbursement and tender pricing

A single global formulation may reduce manufacturing complexity, but regional preservative, labeling, and excipient requirements can prevent full harmonization.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are manageable but meaningful. The main risks are:

• Incomplete wetting or dissolution of sulfacetamide sodium
• Emulsion separation
• Viscosity drift
• Air entrapment
• Preservative failure
• Inconsistent filling
• Container interaction
• Microbial contamination during repeated use

Critical process parameters may include phase temperature, mixing sequence, homogenization energy, cooling rate, pH adjustment, and deaeration. The product should be evaluated in its commercial container because pump, tube, or bottle selection can change dose delivery and contamination risk.

The strongest operational advantage may come from robust process control rather than exclusivity. A manufacturer that delivers consistent semisolid quality, avoids shortages, and supports multiple package configurations can compete effectively even in a low-price generic category.

What is the revenue exposure and commercial value of KLARON?

Standalone KLARON revenue is not a reliable public valuation metric because branded and generic sales may be reported within broader dermatology portfolios. The commercial value is best assessed through:

• Annual prescription volume
• Average selling price
• Generic penetration
• Number of approved or marketed competitors
• Pharmacy substitution rates
• Gross-to-net deductions
• Dermatology channel mix
• Supply reliability
• Cost of goods per filled unit

A basic generic lotion is likely to be a volume product with limited unit economics. A differentiated vehicle can improve pricing, but the addressable market remains narrower than for major acne therapies. The most attractive investment case is a portfolio approach combining KLARON with other topical dermatology products and using shared manufacturing, packaging, regulatory, and distribution infrastructure.

Key Takeaways

• KLARON is a 10% sulfacetamide sodium prescription lotion for acne vulgaris.
• Its established excipient system includes water, fatty alcohols, glycerin, isopropyl myristate, methylparaben, and sodium thiosulfate.
• The legacy product has limited apparent patent strength and long-expired primary exclusivity.
• A near-match generic lotion is the lowest-risk entry strategy but will face price competition.
• The most credible differentiation opportunities are paraben-free preservation, improved sensory performance, alternative dosage forms, pump delivery, and sulfacetamide-sulfur combinations.
• KLARON is a small-molecule drug, so biosimilar competition is not relevant.
• Paragraph IV risk depends on current Orange Book patent listings, not on historic product branding.
• Manufacturing execution, supply reliability, and dermatology distribution are likely to matter more than legacy patent rights.
• A portfolio or licensing strategy is more attractive than a single-product KLARON investment.

FAQs

Is KLARON the same as sulfacetamide sodium lotion?

KLARON is a branded 10% sulfacetamide sodium lotion. A generic product may contain the same active ingredient and strength but can use different inactive ingredients if it satisfies FDA equivalence and quality requirements.

Can KLARON be reformulated as a non-comedogenic product?

Yes, but a non-comedogenic positioning would require a revised vehicle and appropriate substantiation. The sponsor would need to evaluate oil-phase selection, skin deposition, irritation, sensory properties, and product performance.

Does KLARON have a biosimilar competitor?

No. Sulfacetamide sodium is a small molecule. Competitive products would use the ANDA or another small-molecule drug approval pathway, not the biosimilar pathway.

Can a company patent a new KLARON container?

Potentially. A container patent could cover dose metering, contamination control, dispensing geometry, or stability protection. The commercial value would depend on whether the package produces a measurable performance advantage.

Is sulfacetamide sodium still commercially relevant in dermatology?

Yes, but it occupies a niche relative to retinoids, benzoyl peroxide, clindamycin combinations, dapsone, and azelaic acid. Its opportunity is strongest in generic dermatology portfolios and differentiated topical delivery systems.

References

1. U.S. Food and Drug Administration. (n.d.-a). KLARON- sulfacetamide sodium lotion, 10% prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.-b). Product-specific guidances for generic drug development. FDA.

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.-d). Drugs@FDA: FDA-approved drugs. FDA.

5. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 314: Applications for FDA approval to market a new drug. U.S. Government Publishing Office.

6. U.S. Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.